By Ngoc-Anh Hoang

I presented my research findings at the European Scientific Conference on Applied Infectious Disease Epidemiology (ESCAIDE) held in Stockholm, Sweden from November 23 to 25, 2022. This trip was part funded by the Baume HDR Travel Award.  The conference served as a platform for esteemed scientists, researchers, and public health professionals to share knowledge and discuss the latest advancements in the field of infectious disease epidemiology.

During my presentation titled "Assessing the robustness of SARS-CoV-2 vaccine efficacy trials: systematic review and meta-analysis," I focused on evaluating the robustness of all SARS-CoV-2 vaccine efficacy trials published worldwide using the Fragility Index. Through a comprehensive systematic review and meta-analysis, I examined 40 outcomes from 29 randomized control trials. The results revealed significantly higher levels of trial robustness compared to any other trials and interventions. The Fragility Index, a novel and intuitive metric for quantifying trial robustness, was employed. However, it should be considered as a complementary measure rather than a replacement for existing trial parameters such as confidence intervals and p-values. My research contributed to our understanding of vaccine efficacy, bolstered the credibility of trial results, and provided valuable insights for policymakers and public health authorities.